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Abstract: Background & Aims: Interferon reportedly decreases the
incidence of hepatocellular carcinoma (HCC) in patients with chronic
hepatitis C. The Hepatitis C Antiviral Long-term Treatment against
Cirrhosis (HALT-C) Trial showed that 4 years of maintenance therapy
with pegylated interferon (peginterferon) does not reduce liver dis-
ease progression. We investigated whether peginterferon decreases
the incidence of HCC in the HALT-C cohort over a longer posttreat-
ment follow-up period.
Methods: The study included 1048 patients with chronic hepatitis C
(Ishak ﬁbrosis scores P3) who did not have a sustained virologic
response (SVR) to therapy. They were randomly assigned to groups
given a half-dose of peginterferon or no treatment (controls) for
3.5 years and followed up for a median of 6.1 (maximum, 8.7) years.
Results: Eighty-eight patients developed HCC (68 deﬁnite, 20 pre-
sumed): 37 of 515 who were given peginterferon (7.2%) and 51 of
533 controls (9.6%; p = 0.24). There was a signiﬁcantly lower inci-
dence of HCC among patients given peginterferon therapy who had
cirrhosis, but not ﬁbrosis, based on analysis of baseline biopsy sam-
ples. After 7 years, the cumulative incidences of HCC in treated and
control patients with cirrhosis were 7.8% and 24.2%, respectively
(hazard ratio [HR], 0.45; 95% conﬁdence interval [CI], 0.24–0.83);
in treated and control patients with ﬁbrosis, incidences were 8.3%
and 6.8%, respectively (HR, 1.44; 95% CI, 0.77–2.69). Treated patients
with aP2-point decrease in the histologic activity index, based on a
follow-up biopsy, had a lower incidence of HCC than those with
unchanged or increased scores (2.9% vs. 9.4%; p = 0.03).Journal of Hepatology 20
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Although the achievement of a sustained virological response
(SVR) is the endpoint of any Interferon-alpha (IFN) based anti viral
treatment for patients with chronic hepatitis C virus (HCV) infec-
tion, its ultimate goal is to actually attenuate the progression rate
to cirrhosis and the development of life threatening sequelae,
namely hepatocellular carcinoma (HCC), liver decompensation,
and variceal bleeding [1]. In the last years consistent evidence
has emerged that these endpoints are indeed achievable once a
SVR is obtained, both in non cirrhotic patients, as ﬁbrosis progres-
sion is effectively halted following an SVR, as in those with cirrho-
sis, where a signiﬁcant reduction in the rates of development of
HCC, decompensation or variceal bleeding, that ultimately trans-
lates into increased survival, is seen following sustained viral
clearance [2]. Unfortunately, in the last category of patients, the
key beneﬁts that follow an SVR clash with the low chances of
reaching this endpoint, as cirrhosis is still a major reason for treat-
ment failure to pegylated IFN (PegIFN) and ribavirin (Rbv) therapy
[3]. For this matter, hope was kindled when one prospective trial
demonstrated that in a subgroup of IFN non responsive patients,
prolonged maintenance therapy with 24 months of IFN was asso-
ciated with reduced serum transaminases values, improved histo-
logical grading and staging compared to patients on observation
independently on the achievement of a SVR [4]. When this infor-
mation was coupled with the results emerging from several retro-
spective studies in the late 1990’s, that IFN therapywas associated
with a reduction in the rates of HCC development as compared to
clinical observation, the next logical step was to prospectively
assess if indeed IFN maintenance therapy could provide clinical
beneﬁts to patients with advanced hepatitis C. Therefore, a large
prospective randomized study of PegIFN maintenance therapy
versus observation (HALT-C) was conducted in patients with
bridging ﬁbrosis or cirrhosis and a previous treatment failure to
PegIFN and Rbv [5]. In the original publication, 3.5 years of low
dose PegIFN maintenance therapy in 517 patients did not provide
any beneﬁt compared to observation in 533 patients, in terms of
hard clinical endpoints such as death, decompensation or HCC
development. However, in a recent extended analysis of the12 vol. 56 j 276–278
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original HALT-C study, performed by Lok et al. and focused on the
development of HCC, long-term PegIFN maintenance therapy was
associated with reduced HCC rates in patients with pre-treatment
cirrhosis [6]. Although in the overall population consisting of 1048
patients followed up for a mean period of 6.1 years (0–8.7 years),
the incidence of HCC did not differ between the treated ones com-
pared to the controls (7.2% vs. 9.6%, p = 0.24), when considering
only patients with histological cirrhosis at randomization, a lower
incidence of HCC was seen in the PegIFN maintenance therapy
group (6.8% vs. 15.5%, p = 0.01). The cumulative incidence of
HCC at 3, 5, and 7 years being 2.6%, 5.1%, and 7.8% in the PegIFN
group and 4.0%, 11.1%, and 24.2% in the untreated group (log-rank
test, p = 0.009). At this point to further dissect this surprising
result, the authors conducted several sub analysis in the attempt
to identify in which cirrhotic patients the added beneﬁt of PegIFN
maintenance therapy was more pronounced. By this approach
they identiﬁed the importance of PegIFN therapy duration, as
patients who received treatment for more than 2 years had lower
incidence of HCC compared to those who had to discontinue Peg-
IFN before the 2 year mark (HR, 0.36; 95% CI, 0.16–0.82, p = 0.02),
and also describe a correlation between a decrease in the histolog-
ical activity index (HAI) of at least 2 points in repeat liver biopsies
and a lower risk of HCC development. When analyzing patients
without cirrhosis at baseline, no protective effect of maintenance
therapy was seen, as the incidence of HCC was 7.5% in the treated
ones and 5.4% in the controls (HR 1.44; 95% CI 0.77–2.69, p = 0.26).
Based on these results, the authors very cautiously conclude that
in the extended follow-up of the HALT-C trial a modest beneﬁt of
long term maintenance therapy was seen in reducing the inci-
dence of HCC in cirrhotic patients only, but still, as this effect
was only marginal, PegIFN has an unfavorable side effect proﬁle
and no beneﬁt was seen on mortality rates, the clinical implica-
tions of these results are unclear and the beneﬁts of PegIFN main-
tenance therapy is doubtful.
Although we strongly agree with the authors conclusions, the
study by Lok and colleagues unfortunately might add confusion
to the debate on the potential beneﬁts of PegIFN maintenance
therapy. Indeed this was quite a hot topic in the past years, as
the demonstration of a long term beneﬁt of a low dose PegIFN
regimen would have been quite a clinical, and commercial, break-
through. For this reason the ﬁnal results of 3 randomised con-
trolled studies designed for this endpoint (Table 1) were
eagerly awaited [5,7,8]. Although a direct comparison of the
study results is partially precluded by differences in the patients
characteristics and in the assigned treatment regimens, they
unanimously failed to demonstrate any positive impact of PegIFN
maintenance therapy on HCC incidence rates. The only beneﬁcialTable 1. Study design and results of the 3 RCT on PegIFN maintenance therapy in H
Trial Patients 
No.
Disease stage Treatment regime
HALT-C [5] 1050 Bridging Fibrosis/Cirrhosis Active: PegIFNα2a
Control: Observat
EPIC3 [7] 626 Cirrhosis Active: PegIFNα2b
Control: Observat
COPILOT [8] 555 Bridging Fibrosis/Cirrhosis Active: PegIFNα2b
Control: Colchicin
Journal of Hepatology 201effect seen in 2 studies was a reduced rate of development of gas-
tro-esophageal varices or variceal bleeding in patients receiving
PegIFN maintenance therapy compared to the control group,
eventually suggesting a role of PegIFN in the prevention of the
complications of portal hypertension more than in the develop-
ment of HCC. Regarding HCC development, the question, there-
fore, is whether the extended follow-up of the HALT-C trial
allowed us to ﬁnally see a protective role of PegIFN maintenance
therapy, or if rather this result is just a consequence of chance.
The causal role of PegIFN maintenance therapy is supported by
the many statistical analysis conducted by the HALT-C investiga-
tors to corroborate their results. Moreover, the ﬁnding that
patients who received treatment for more than 2 years or showed
a decrease in HAI of more than 2 points in follow-up liver biop-
sies were the ones really beneﬁtting from prolonged treatment
provides a biological explanation to the study results. Casting
some doubts over the clinical interpretation of these results, is
the fact that the prolongation of an uncontrolled follow-up period
by deﬁnition carries a risk of inherent biases, and probably most
importantly, that the main ﬁnding derives from a subanalysis in
which patients were stratiﬁed in being cirrhotic or non-cirrhotic
by a baseline liver biopsy. Indeed, while liver biopsy is still the
gold standard for ﬁbrosis staging, it is universally acknowledged
that a sampling error may lead to a misdiagnosis of cirrhosis in
up to 30% of the specimens [9]. A misclassiﬁcation of patients
by liver biopsy may in part explain some of the HALT-C results,
as not only PegIFN maintenance therapy resulted in similar
HCC incidence rates compared to controls in non cirrhotic
patients, but in the original paper it was actually associated with
a signiﬁcant higher mortality rate compared to controls (5% vs.
1.9%, p = 0.04) [5]. A result that would effectively suggest that
PegIFN maintenance therapy has the obscure ability to protect
cirrhotic patients from the risk of HCC while on the other hand,
being potentially harmful in those with less advanced ﬁbrosis.
Quite frankly, this seems rather improbable and is likely the con-
sequence of confounding factors we still have not quite yet
understood. It seems, therefore, clear that we are still missing
some key pieces in the maintenance therapy puzzle and that if
such a therapy has a place in the treatment of patients with cir-
rhosis, at this moment we have not yet identiﬁed who these
patients might be. In this context, the positive predictive power
associated with the reduction in HAI score during treatment
should not be overlooked, and efforts should be made to study
if non invasive methods can be used to correctly identify this
set of responders whilst also exploring if host genetic differences
lie behind this different susceptibility to PegIFN maintenance
therapy [10]. If these two points were to be demonstrated, andCV patients with advanced ﬁbrosis and cirrhosis.
n Follow-up period 
(months)
HCC cumulative
incidence 
(Tx vs. Controls)
 90 µg/week
ion
42
42
2.3% vs. 2.8%
 0.5 µg/kg/week 
ion
31.4 ± 16.1
30.2 ± 16.2
4% vs. 4%
 0.5 µg/kg/week
e 0.6 mg/bid
48
48
9.1% vs. 4.4%
2 vol. 56 j 276–278 277
International Hepatology
not forgetting the protective effect seen in patients with portal
hypertension, PegIFN maintenance therapy could ﬁnally exit
the limbo of mythology and enter the clinical practice for a niche
of patients.Conﬂict of interest
M.C. has received grants and research support from Merck,
Roche, BMS, and Gilead Science; belongs to the advisory commit-
tees of Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibo-
tec, and Vertex; and has spoken and taught for Tibotec, Roche,
Novartis, Bayer, BMS, Gilead Science, and Vertex. A.A. belongs
to the advisory board of Roche and received travel support from
Roche, Bayer, Glaxo Smith Kline, and Bristol Myers.References
[1] European Association for the Study of the Liver. EASL Clinical Practice
Guidelines: Management of hepatitis C virus infection. J Hepatol
2011;55(2):245–264.
[2] Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al.
Sustained virological response to interferon-alpha is associated with278 Journal of Hepatology 201improved outcome in HCV-related cirrhosis: a retrospective study 3.
Hepatology 2007;45:579–587.
[3] Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic
response in hepatitis B and C. J Hepatol 2008;49:634–651.
[4] Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK,
et al. A randomized, controlled trial of maintenance interferon therapy for
patients with chronic hepatitis C virus and persistent viremia. Gastroenter-
ology 1999;117 (5):1164–1172.
[5] Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright
EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose
peginterferon. N Engl J Med 2008;359 (23):2429–2441.
[6] Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, et al.
Maintenance peginterferon therapy and other factors associated with
hepatocellular carcinoma in patients with advanced hepatitis C. Gastroen-
terology 2011;140:840–849.
[7] Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, et al.
Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepa-
tocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. Gastro-
enterology 2011;140 (7):1990–1999.
[8] Afdhal N, Levine R, Brown R Jr, et al. Colchicine versus peginterferon alfa 2b
long-term therapy: results of the 4 year COPILOT trial (oral presentation).
Presented at: 43rd Annual Meeting of the European Association for the Study
of the Liver; April 23–27, 2008; Milan, Italy.
[9] Manning DS, Afdhal NH. Diagnosis and quantitation of ﬁbrosis. Gastroen-
terology 2008;134 (6):1670–1681.
[10] Clark PJ, Thompson AJ, McHutchison JG. Genetic variation in IL28B: impact
on drug development for chronic hepatitis C infection. Clin Pharmacol Ther
2010;88 (5):708–711.2 vol. 56 j 276–278
